A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.
Saunders, Mark P
Valle, Juan W
Lorigan, Paul C
Wardley, Andrew M
Cowan, Richard A
Loncaster, Juliette A
AffiliationSchool of Nursing, Midwifery and Social Work, University of Manchester, Coupland III, Manchester, UK. email@example.com
MetadataShow full item record
AbstractOBJECTIVE: The aim of the study was to assess levels of chemotherapy-induced nausea and vomiting (CINV) in routine practice. MATERIALS AND METHODS: The study was an observational prospective evaluation using patient self-reports. One hundred and two patients with cancer in a single cancer centre in UK receiving their first chemotherapy treatment participated in the study and were followed up over four cycles, providing a total of 272 assessments of nausea and vomiting. Data was collected with the use of the MASCC Antiemesis Tool (MAT), which is an eight-item short clinical scale assessing acute and delayed nausea and vomiting after chemotherapy. RESULTS: Results indicated that acute vomiting was experienced by 15.7% of the patients in cycle 1 and delayed vomiting by 14.7%, while acute nausea was present in 37.3% of the patients and delayed nausea in 47.1%, increasing over the subsequent cycles. Moderately emetogenic and highly emetogenic chemotherapy had the highest incidence of CINV, whereas patients receiving highly emetogenic chemotherapy showed significant levels of delayed nausea. Acute symptoms were more easily controlled than delayed symptoms. DISCUSSION: The data suggest that, while vomiting is well controlled, nausea remains a significant problem in practice, and optimal management of CINV is yet to be achieved. Understanding more clearly the biological basis of nausea will assist in managing this complex symptom more effectively in practice.
CitationA prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. 2008, 16 (2):201-208 Support Care Cancer
JournalSupportive Care in Cancer
- Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
- Authors: Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS
- Issue date: 2005 May
- Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
- Authors: Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F
- Issue date: 2014 May
- Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
- Authors: Warr JK, Chambers CR, Cusano FL, Cuthbert CA, Mah MS
- Issue date: 2015 Oct
- Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
- Authors: Matsuda Y, Okita K, Furuhata T, Kutomi G, Yamashita K, Sato Y, Takimoto R, Hirata K
- Issue date: 2015 Nov
- Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
- Authors: Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J
- Issue date: 2006 Sep 20